Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 90

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Metastases to central nervous system+1

Not recruiting

Study on the Effects of Losartan Potassium on Brain Tumors in Patients with Glioblastoma or Brain Metastases from Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Losartan Potassium
  • Sponsor:Oslo University Hospital HF

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Fasudil Hydrochloride for Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fasudil Hydrochloride
  • Sponsor:Klinikum rechts der Isar der TU Muenchen AöR

Duchenne muscular dystrophy

Not recruiting

Study on DMD06-MAB Injection for Duchenne Muscular Dystrophy in Non-Ambulant Patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:DMD06-MAB
  • Sponsor:Ospedale San Raffaele S.r.l.

Metachromatic leukodystrophy

Not recruiting

Study on Gene Therapy with Atidarsagene Autotemcel for Patients with Metachromatic Leukodystrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Spinal muscular atrophy

Not recruiting

Study of NMD670 tablets to improve muscle strength in adults with TYPE 3 spinal muscular atrophy who can walk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NMD670
  • Sponsor:NMD Pharma A/S

Myasthenia gravis

Not recruiting

Study on Efgartigimod IV for Adults with Seronegative Generalized Myasthenia Gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Metachromatic leukodystrophy

Not recruiting

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Relapsing-remitting multiple sclerosis

Not recruiting

Study on Testosterone Undecanoate for Neuroprotection and Myelin Repair in Patients with Relapsing Remitting Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Testosterone Undecanoate
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Migraine

Not recruiting

Study on the Effectiveness of Fremanezumab for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Fremanezumab
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Relapsing multiple sclerosis

Not recruiting

Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Duchenne muscular dystrophy

Not recruiting

Study on Long-Term Safety and Effectiveness of Vamorolone in Boys with Duchenne Muscular Dystrophy Who Completed Previous Vamorolone Studies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vamorolone
  • Sponsor:Santhera Pharmaceuticals (Schweiz) AG

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.